Download PDF
Thromb Haemost 1994; 71(03): 275-279
DOI: 10.1055/s-0038-1642429
Original Article
Schattauer GmbH Stuttgart

Increased Tissue Factor Pathway Inhibitor Levels in Uremic Patients on Regular Hemodialysis

Kazuomi Kario
1   The Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo, Japan
2   The Department of Internal Medicine, Awaji-Flokutan Public Clinic, Hokutan, Tsuna, Hyogo, Japan
,
Takefumi Matsuo
1   The Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo, Japan
,
Tsutomu Yamada
1   The Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo, Japan
,
Miyako Matsuo
1   The Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo, Japan
› Author Affiliations
Further Information

Publication History

Received: 29 July 1993

Accepted after revision 16 December 1993

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We investigated tissue factor pathway inhibitor (TFPI) levels in 44 non-dialysis uremic patients and 36 chronic dialysis patients, as well as the changes of TFPI levels during hemodialysis sessions using heparin (n = 14), low molecular weight heparin (n = 7), nafamostat mesilate (n = 5), and argatroban (n = 2). In non-dialysis uremic patients, TFPI levels increased (mean ± SD: 178 ± 37% of control pooled plasma) along with the impairment of renal function. In chronic hemodialysis patients, TFPI levels were even higher (265 ± 72%) before dialysis, but did not depend on the etiology of renal failure (diabetic or non-diabetic), the interval between dialysis sessions (twice or three times a week), and the duration of hemodialysis. During hemodialysis sessions using heparin, TFPI levels increased 1.2-to 3.5-fold compared with the level before hemodialysis and the degree of increase in TFPI was correlated with the heparin concentration (r = 0.648, p = 0.0001, n = 29). During dialysis sessions using low molecular weight heparin, TFPI levels also increased, but the change was less marked than during dialysis with heparin. TFPI levels did not change during dialysis sessions using nafamostat mesilate or argatroban. In conclusion, TFPI levels were increased by renal failure and by long-term repeated injection of heparin, but the hemodialysis procedure itself did not alter the TFPI level.

 

  • References

  • 1 Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991; 58: 201-4
    CrossrefPubMedGoogle Scholar
  • 2 Sorensen PJ, Knudsen F, Bielsen AH, Dyerberg J. Protein C assays in uremia. Thromb Res 1989; 54: 301-10
    CrossrefPubMedGoogle Scholar
  • 3 Toulon P, Jacquot C, Capron L, Frydman M-O, Vignon D, Aisch M. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemostas 1987; 57: 263-8
    PubMedGoogle Scholar
  • 4 Yamazaki M, Asakura H, Sato T, Tsugawa Y, Matsumura M, Kawamura Y, Ohka T, Matsuda T. Changes in plasma levels of thrombomodulin during haemodialysis. Blood Coag Fibr 1992; 3: 113-7
    PubMedGoogle Scholar
  • 5 Rapaport SI, Rao LV M. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21
    CrossrefPubMedGoogle Scholar
  • 6 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR S, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7
    PubMedGoogle Scholar
  • 7 Kario K, Matsuo T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992; 67: 105-13
    CrossrefPubMedGoogle Scholar
  • 8 Fridman EA. Outcome and complications of chronic hemodialysis. In: Diseases of the kidney Schrier RW, Gottschalk CW. (eds). Boston/Toronto: Little, Brown and Company Inc; 1998: 3323-43
  • 9 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostas 1991; 66: 6-15
    PubMedGoogle Scholar
  • 10 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93
    PubMedGoogle Scholar
  • 11 Sandset PM, Abildgaard U. Extrinsic pathway inhibitor-the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39
    PubMedGoogle Scholar
  • 12 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibr 1992; 3: 439-49
    PubMedGoogle Scholar
  • 13 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13
    CrossrefPubMedGoogle Scholar
  • 14 Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991; 21: 254-7
    PubMedGoogle Scholar
  • 15 Lindahl AK, Abildgaard U, Larsen ML, Aamodt L-M, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991. (Suppl. XIV): 39-48
    Google Scholar
  • 16 Novotny WF, Palmier M, Wun T-C, Broze Jr GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1992; 178: 394-400
    PubMedGoogle Scholar
  • 17 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23 (suppl 1): 103-6
    PubMedGoogle Scholar
  • 18 Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophy Res Commun 1981; 101: 440-6
    CrossrefPubMedGoogle Scholar
  • 19 Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Brit J Haematol 1992; 82: 627-9
    CrossrefPubMedGoogle Scholar
  • 20 Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost 1992; 18: 155-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15: 164-8
    PubMedGoogle Scholar
  • 22 Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23: 135-41
    PubMedGoogle Scholar
  • 23 Sandset PM, Larsen ML, Abildgaard U, Lindahl KA, Odegaard OR. Chro-mogenic substrate assay of extrinsic pathway inhibitor (EPI): levels of the normal population and relation to cholesterol. Blood Coag Fibr 1991; 2: 425-33
    PubMedGoogle Scholar
  • 24 Kario K, Matsuo T, Nakao K. Factor VII hyperactivity in the elderly. Thromb Haemostas 1991; 65: 25-7
    PubMedGoogle Scholar
  • 25 Kario K, Matsuo T. Coronary artery disease and factor VII hyperactivity in elderly Japanese. Am J Cardiol 1992; 69: 807-9
    CrossrefPubMedGoogle Scholar
  • 26 Boyer C, Wolf M, Rothschild C, Migaud M, Amiral J, Mannuci PM, Meyer D, Larrieu MJ. An enzyme immunoassay (Elisa) for the quantification for human factor VII. Thromb Haemostas 1986; 56: 250-6
    PubMedGoogle Scholar
  • 27 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9
    PubMedGoogle Scholar
  • 28 Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibody to discrete regions in α2-plasmin inhibitor. Blood 1987; 69: 446-53
    PubMedGoogle Scholar
  • 29 Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-6
    PubMedGoogle Scholar
  • 30 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-9
    PubMedGoogle Scholar
  • 31 Kario K, Matsuo T, Kobayashi H, Matsuo M, Yamamoto K, Sakurai G, Baba M. Rapid quantitative evaluation of plasma D-dimer levels in thrombotic states using an automated latex photometric immunoassay. Thromb Res 1992; 66: 179-89
    CrossrefPubMedGoogle Scholar
  • 32 Holmer E, Soderberg K, Friberger P, Sorskog L. A new simple chromo-genic assay for heparin and heparin-like anti-FXa activity in plasma. Thromb Haemostas (abstract) 1985; 54: 29
    PubMedGoogle Scholar
  • 33 Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG E, Wun T-C. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemostas 1992; 68: 33-6
    PubMedGoogle Scholar
  • 34 Speiser W, Wojta J, Kominger C, Kirchheimer JC, Zazgornik J, Binder BR. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int 1987; 32: 280-3
    CrossrefPubMedGoogle Scholar